Canaccord analyst Bill Maughan raised the firm’s price target on Merus to $54 from $45 and keeps a Buy rating on the shares. The firm said they continue to see the company’s bispecific antibody platform as differentiated and believe positive peto data in 2Q would further validate the platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRUS:
- Merus price target raised to $65 from $48 at H.C. Wainwright
- Merus files automatic mixed securities shelf
- Merus reports 2023 EPS ($3.00), consensus ($2.68)
- Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
- Merus NV (MRUS) Q4 Earnings Cheat Sheet
